Financings – Cont. from Vital Signs 12/1/23
more
We had several financings that didnt make the 12/1 edition of Vital Signs.

Biolexis Therapeutics – a company using AI for metabolic drug discovery, raised a $10M Series A. (American Fork, UT)

Aperiam Bio – a protein engineering company, raised a $9M Seed extension.(Brooklyn, NY)

Arrivo Bioventures – a drug developer, raised a $45M Series B.(Morrisville, NC)
Facebook
Twitter
LinkedIn

Recent Posts

Is The Venture Capital Party Over?

Mark Twain famously said “The reports of my death are greatly exaggerated.” Such is the…

Ai Juggernaut Palantir Enters Healthcare

Palantir is not exactly a household name, but the Peter Thiel founded company now based…

PE Perspectives

Triple Tree and Bain & Co are two very sharp private equity firms and when…